CALGB 9840: Phase III study of weekly (W) paclitaxel (P) via 1-hour(h) infusion versus standard (S) 3h infusion every third week in the treatment of metastatic breast cancer (MBC), with trastuzumab (T) for HER2 positive MBC and randomized for T in HER2 normal MBC Meeting Abstract


Authors: Seidman, A. D.; Berry, D.; Cirrincione, C.; Harris, L.; Dressler, L.; Muss, H.; Norton, L.; Winer, E.; Hudis, C.
Abstract Title: CALGB 9840: Phase III study of weekly (W) paclitaxel (P) via 1-hour(h) infusion versus standard (S) 3h infusion every third week in the treatment of metastatic breast cancer (MBC), with trastuzumab (T) for HER2 positive MBC and randomized for T in HER2 normal MBC
Meeting Title: 40th Annual Meeting of the American Society of Clinical Oncology (ASCO)
Journal Title: Journal of Clinical Oncology
Volume: 22
Issue: 14 Suppl.
Meeting Dates: 2004 Jun 5-8
Meeting Location: New Orleans, LA
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 2004-07-15
Start Page: 6S
Language: English
ACCESSION: WOS:000223512400020
PROVIDER: wos
Notes: Meeting Abstract: 512 -- 40th Annual Meeting of the American-Society-of-Clinical-Oncology -- JUN 05-08, 2004 -- New Orleans, LA -- S -- Source: Wos